BackVectus Biosystems Limited Overview

Vectus Biosystems Limited Current Assets

Track Vectus Biosystems Limited's current assets ($3.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$3.80M
↑ 388.26% YoYΔ $3.02M vs prior year quarter

Peer trimmed avg / median

Loading

Vectus Biosystems Limited Current Assets History

Loading

Vectus Biosystems Limited vs. peers: Current Assets Comparison

Loading

Vectus Biosystems Limited Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Vectus Biosystems Limited (VBS.AX) FAQ

Vectus Biosystems Limited's current assets stands at $3.8M as of June 2026. That compares with $780K in the prior-year period — up 388.3% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Vectus Biosystems Limited reported $3.8M in current assets versus $780K a year earlier — a 388.3% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $780K in the prior-year period — up 388.3% year over year. Sustained growth in current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Vectus Biosystems Limited's current assets evolved across reporting periods, while the comparison chart places VBS.AX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current assets is commonly used to spot outliers. Vectus Biosystems Limited's reading of $3.8M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.